27: Best abstract: A multicentre, double-blind, placebo-controlled phase3 study of ustekinumab, a human interleukins-12/23p40 mab, in moderate-severe Crohn’s Disease refracto-ry to anti-TNFα: UNITI-1ECCO'16 Amsterdam
2016
1
28: Best abstract: Results of ANDANTE, a randomised clinical study with an anti-IL6 antibody (PF-04236921) in subjects with Crohn’s Disease who are anti-TNF inadequate respondersECCO'16 Amsterdam
2016
1
2: Clinical trial terminology & processes. Standard investigations1st School for Clinical Trialists
2016
1
2: Diagnosis, treatment and outcomes of Paediatric IBD Unclassified (IBD-U)3rd P-ECCO Educational Course
2016
1
2: Human monogenetic IBD patients – Insights into disease pathogenesis Molecular aetiology of IBD
2016
1
2: Research priorities – overview of findings from the Delphi survey3rd N-ECCO Research Forum
2016
1